MedTrace Logo

The Relationship Between Gait and Severity of Femoroacetabular Impingement

NCT06536088 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-08-02

No results posted yet for this study

Summary

In this study, the spatiotemporal gait parameters of symptomatic femoroacetabular impingement (FAI) patients scheduled for hip arthroscopy are evaluated. Radiological measurements, including the Alpha angle (AA), Lateral Center-Edge Angle (LCEA), and Kellgren-Lawrence (KL) osteoarthritis classification, are recorded from patient files. The relationship between these radiological measurements and walking parameters is assessed. Additionally, the spatiotemporal gait parameters of FAI patients are compared with those of a healthy control group.

Walking assessments provide valuable insights into how Femoroacetabular Impingement (FAI) affects movement and aid in evaluating treatment outcomes. Research indicates that individuals with FAI experience reduced hip motion and slower walking speeds. By analyzing spatiotemporal gait parameters-such as gait velocity, cadence, step length, and vertical center of mass-the impact of FAI on walking can be better understood, leading to the development of targeted treatment strategies. The goal is to explore the correlation between these gait parameters and imaging-based FAI characteristics in affected individuals.

Conditions

  • Femoroacetabular Impingement

Interventions

OTHER

Walking assesment

Spatiotemporal walking assessments are performed using the Gait Analyzer app (version 0.9.95.0) on a smartphone. Participants who can walk independently without assistance walk a 25-meter path at their normal speed, with the smartphone securely attached to their body above the third lumbar vertebra using a belt. The app records gait velocity, cadence, step time, step length, and vertical center of mass for all participants.

Sponsors & Collaborators

  • Gazi University

    lead OTHER

Principal Investigators

  • Ulunay Kanatlı, Professor · Gazi University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-09-30
Completion
2024-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536088 on ClinicalTrials.gov